Literature DB >> 11390574

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

J P Moore1, P W Parren, D R Burton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11390574      PMCID： PMC114288          DOI： 10.1128/JVI.75.13.5721-5729.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  131 in total

Review 1.  The 1918 influenza virus: A killer comes into view.

Authors:  J K Taubenberger; A H Reid; T G Fanning
Journal:  Virology       Date:  2000-09-01       Impact factor: 3.616

2.  Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.

Authors:  H Cao; I Mani; R Vincent; R Mugerwa; P Mugyenyi; P Kanki; J Ellner; B D Walker
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

4.  HIV-1 antibody--debris or virion?

Authors:  P W Parren; D R Burton; Q J Sattentau
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

5.  Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160.

Authors:  E Decroly; S Benjannet; D Savaria; N G Seidah
Journal:  FEBS Lett       Date:  1997-03-17       Impact factor: 4.124

6.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.

Authors:  N Vidal; M Peeters; C Mulanga-Kabeya; N Nzilambi; D Robertson; W Ilunga; H Sema; K Tshimanga; B Bongo; E Delaporte
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.

Authors:  M W Cho; M K Lee; C H Chen; T Matthews; M A Martin
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  HIV-1 membrane fusion: targets of opportunity.

Authors:  R W Doms; J P Moore
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

10.  Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.

Authors:  G B Melikyan; R M Markosyan; H Hemmati; M K Delmedico; D M Lambert; F S Cohen
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539
View more
  32 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

3.  Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M.

Authors:  Martin Baril; Dominic Dulude; Karine Gendron; Guy Lemay; Léa Brakier-Gingras
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

4.  Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Authors:  Melissa E Laird; Ronald C Desrosiers
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.

Authors:  Qian Wang; Wenwen Bi; Xiaojie Zhu; Haoyang Li; Qianqian Qi; Fei Yu; Lu Lu; Shibo Jiang
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

6.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.